Update on Adjuvant Therapy of Colon Cancer

American Cancer Society: Cancer facts and figures-1995, p. 6, 1995.

Anonymous. The efficacy and the group C status of levamisole and 5-fluorouracil for patients with Dukes’ C colon cancer. National Cancer Institute Update, October, 1989.

Buyse M. , Zeleniuch-Jacquotte A. , Chalmers T.C. : Adjuvant therapy of colon cancer: why we still don't know. JAMA, 259: 3571–3578, 1988.

Crowley J.J. : Perioperative portal vein chemotherapy. ASCO Educational Book, p. 171, 1994.

de Haas-Kock D. , Baeten C. , Jager J. , Langendijk Schouten L. , Arends J. : The prognostic significance of the lateral resection margin in rectal cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, Germany, January 1995.

Francini G. , Petrioli R. , Lorenzini L. , Mancini S. , Armenio S. , Tanzini G. , Marsil S. , Aquino A. , Marzocca G. , Civitellis C. , Mariani L. , De Sando D. , Bovenga S. , Lorenzi M. : Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology, 106: 899–906, 1994.

Haller D.G. , Catalano P.J. , Macdonald J.S. , Mayer R.J. : Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc. Am. Soc. Clin. Oncol., 15: 486; 1996.

Hodi F.S. , Catalano P. , Macdonald J.S. , Mayer R.J. , Haller D.G. : Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Pending submission, 8/96.

International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939–944, 1995.

Moertel C.G. , Fleming T.R. , Macdonald J.S. : Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J. Clin. Onc., 11: 2386–2390, 1993.

Moertel C.G. , Fleming T.R. , Macdonald J.S. , Haller D.G. , Laurie J.A. , Tangan C.M. , Ungerleider J.S. , Eerson W.A. , Tormey D.C. , Glick J.H. , Veeder M.H. , Maillaird J.A. : Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Int. Med., 122: 321–326, 1995.

Moertel C.G. , Fleming T.R. , Macdonald J.S. , Haller D.G. , Laurie J.A. , Goodman P.J. , Ungerleider J.S. , Emerson W.A. , Tormey D.C. , Glick J.H. , Veeder M.H. , Mailliard J.A. : Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352–358, 1990.

O'Connell J.M. , Laurie J.A. , Shepherd L. , Kahn M.J. , Pazdur R. , Fitzgibbons R.J. , Erlichman C. , Wieand H.S. : A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and The National Cancer Institute of Canada Clinical Trials Group. Proc. Am. Soc. Clin. Oncol., 15: 478, 1996.

O'Connell M. , Mailliard J. , Macdonald J.S. : An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc. Am. Soc. Clin. Oncol., 12: 190, 1993.

Piedbois P. , Buyse M. , Gray R. , Clarke M. , Wolkmark N. , Metzger V. , Fielding L.P. , Gray P. , Taylor I. , Wereldsma J. , Ryan J. , Marsoni S. , Gruenagel H.H. : Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol., 14: 192, 1995.

Riethmuller G. , Schneider-Gadicke E. , Schlimok G. , Schmiegel W. , Raab R. , Hoffken K. , Gruber R. , Pichlmaier H. , Hirche H. , Pichlmayr R. , Buggisch P. , Witte J. : Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet, 343: 1177–183, 1994.

Wolmark N. , Rockette H. , Mamounas E.P. , Jones J. , Petrelli N. , Atkins J. , Dimitrov N. , Pugh R. , Wickerham D.L. , Wieand S. , Fisher B. : The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes’ B and C carcinoma of the colon: First Report of NSABP C0-4. Proc. Am. Soc. Clin. Oncol., 15: 460, 1996.